GVI Clinical Development Solutions and Guangzhou IRD Medicine Company Create Global CRO
News May 04, 2011
GVI Clinical Development Solutions Inc. (CDS), headquartered in Winnipeg, Canada and Guangzhou, China based Guangzhou IRD Medicine Company, have announce the signing of a Memorandum of Understanding to create a joint venture company called IRD-CDS, based in China.
IRD-CDS is committed to providing excellence in clinical development services and expertise in the conduct of clinical trials.
"We are very pleased to have formalized our relationship with Guangzhou IRD Medicine Company through the creation of IRD-CDS," commented Jan-Ake Westin, President of CDS. "Their in-depth knowledge of the life science industry in China combined with our team's expertise in conducting global clinical trials makes for a strong partnership that is ready to meet the needs of clinical stage companies."
IRD-CDS' flexibility and active participation during the critical stages of the clinical development process make it an ideal clinical partner for life science companies who want to take advantage of the expanding clinical trial environment in China.
The CDS group has tremendous global experience in clinical research trials and strong relationships within the industry. Current clients include world class research hospitals, multinational and emerging life science companies.
IRD-CDS is a full service contract research organization supporting biotechnology, pharmaceutical, diagnostic, medical device, and nutraceutical companies looking to conduct Phase II & III clinical trials in China.
Many life-saving medicines, including insulin, antibodies and vaccines, are derived from living cells. These “biologics” can be difficult to obtain and store on the battlefield or in remote areas. That’s why scientists are trying to develop portable systems that can quickly manufacture small batches of protein therapeutics on demand.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019